Live coverage of the 19th Winter Clinic in Kauai

A simple overview of the treatment pipeline holds great promise for dermatologists looking for options for their most challenging patients. And a look at the agenda for the upcoming 19th Anniversary Winter Clinical Dermatology In-Person Conference, which begins Friday, January 14, 2022, in Kauai, shows just how well the dermatologists in attendance and those of you who stay tuned Dermatology Times® all weekend to read our live coverage of the reunion, will inquire about these options.

To start the meeting, Dermatology Times® Editorial board member Mark Lebwohl, MD, will moderate a hard case session on Friday evening. Lebwohl said Dermatology Times® he looks forward to a “busy” meeting.

“Historically, Winter Clinical has been jam-packed with useful information, and this year will be no different,” he said. “Clinical guidance that you can use immediately has always been a feature of this meeting.” He said the next few months and years will be exciting, with “new treatments for rare disorders like generalized pustular psoriasis, elastic pseudoxanthoma and blast plasmacytoid dendritic cell neoplasm” to be discussed.

Other featured sessions on this weekend’s coverage will include a focus on what’s hot in infectious disease, by Ted Rosen, MD, professor of dermatology at Baylor College of Medicine in Houston, Texas, which will include without any doubt some thoughts on the recent spike in COVID-19 cases and a talk on some of the latest advances in treatments for a range of infectious diseases.

A central challenge in dermatology is treating pediatric patients with skin problems, and Peter A. Lio, MD, who is a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, will address this. issue in his talk, “What’s Hot in Pediatric Dermatology.” Her session will focus on some recently published data suggesting that a commonly used atopic dermatitis treatment can alleviate some symptoms of COVID-19. He will also discuss recently published data from phase 3 studies that show the efficacy and good tolerability of a drug-device combination containing 0.7% cantharidin (VP-102; Verrica) used to treat molluscum contagiosum.

Throughout the weekend, we will also cover a range of topics from the meeting, including the latest innovations in aesthetic treatments, the best in oncology and biologics, and the latest technological innovations to treat your patients and keep your practice up to date. .

Comments are closed.